source
- STAT+: Otsuka kidney drug slowed loss of function, but less than expected, in late-stage trialOtsuka’s Voyxact slowed the loss of kidney function after one year in patients with a chronic autoimmune kidney disease, but the benefit was less than expected.STAT · 1mo ago↗ source
- Acting FDA chief isn't interested in permanent roleActing FDA Commissioner Kyle Diamantas isn't interested in keeping the job and the search for a permanent replacement is progressing, according to a source familiar with the process. An announcemen…Endpoints · 1mo ago↗ source
- STAT+: Supreme Court backs generic drugmaker in ‘skinny labeling’ caseThe Supreme Court unanimously ruled that Hikma Pharmaceutical did not infringe patents held by Amarin in a decision with implications for lawsuits over so-called skinny labels.